title: Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays.
abstract: Although breast cancer molecular subtypes have been extensively defined by means of gene expression profiling over the past decade, little is known, at the proteomic level, as to how signaling pathways are differentially activated and serve to control proliferation in different breast cancer subtypes. We used reverse-phase protein arrays to examine phosphorylation status of 100 proteins in a panel of 30 breast cancer cell lines and showed distinct pathway activation differences between different subtypes that are not obvious from previous gene expression studies. We also show that basal levels of phosphorylation of key signaling nodes may have diagnostic utility in predicting response to selective inhibitors of phosphatidylinositol 3-kinase and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase. Finally, we show that reverse-phase protein arrays allow the parallel analysis of multiple pharmacodynamic biomarkers of response to targeted kinase inhibitors and that inhibitors of epidermal growth factor receptor and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase result in compensatory up-regulation of the phosphatidylinositol 3-kinase/Akt signaling pathway.
authors.affiliation: Department of Development Oncology Diagnostics, Genentech, Inc., South San Francisco, California 94080, USA.
authors.forename: Zachary S
authors.initials: ZS
authors.lastname: Boyd
authors.forename: Qun Jenny
authors.initials: QJ
authors.lastname: Wu
authors.forename: Carol
authors.initials: C
authors.lastname: O'Brien
authors.forename: Jill
authors.initials: J
authors.lastname: Spoerke
authors.forename: Heidi
authors.initials: H
authors.lastname: Savage
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Fielder
authors.forename: Lukas
authors.initials: L
authors.lastname: Amler
authors.forename: Yibing
authors.initials: Y
authors.lastname: Yan
authors.forename: Mark R
authors.initials: MR
authors.lastname: Lackner
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D016000:Cluster Analysis; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D006801:Humans; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D010766:Phosphorylation; D040081:Protein Array Analysis; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D040901:Proteomics / Q000379:methods*; D034741:RNA, Small Interfering / Q000378:metabolism; D015398:Signal Transduction
chemical_list: D014408:Biomarkers, Tumor; D004791:Enzyme Inhibitors; D047428:Protein Kinase Inhibitors; D034741:RNA, Small Interfering; D019869:Phosphatidylinositol 3-Kinases; D048049:Extracellular Signal-Regulated MAP Kinases